{
  "title": "Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trialGlobal cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesPerioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialHistopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialPerioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancerTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerPembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialEfficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial.Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trialPerioperative durvalumab in gastric and gastroesophageal junction cancerNeoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyPhase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: the role of M2 macrophage landscape in predicting responseTrastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study GroupPerioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIOEORTC-1203 GITC \u201cINNOVATION\u201d: integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: overall survival resultsImmune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophagesTrastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretionFirst-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trialInflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted therapy and immunotherapyPredictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: a systematic review and meta-analysisPembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialOutcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancerTrastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialNonoperative management of mismatch repair\u2013deficient tumors.Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 studyPD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer.Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapyResults of the observational prospective RealFLOT studyPhase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinomaOptimization of detection of residual disease after neoadjuvant therapy in patients with esophageal cancerAccuracy of 18F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancerTrial: surgery as needed versus surgery on principle in patients with postneoadjuvant clinical complete tumor response of esophageal cancerNeoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialIncidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabSingle-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitisTFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialFLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study groupPhase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer.",
  "pmcid": "12705456",
  "features": {
    "sample_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "randomization": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "variable_definitions": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "primary endpoint"
      ],
      "examples": [
        {
          "match": "primary endpoint",
          "context": "mately 1 year. The study\u2019s co-primary endpoints are the 2-year disease-free"
        },
        {
          "match": "primary endpoint",
          "context": "nts, and missing data for the primary endpoint were considered failures. In"
        }
      ]
    },
    "analysis_principles": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "itt"
      ],
      "examples": [
        {
          "match": "ITT",
          "context": "Pathological response in the ITT population FOOTER: n, number"
        },
        {
          "match": "ITT",
          "context": "Pathological response in the ITT population based on CPS score"
        }
      ]
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "r version 3.6.1",
        "sas"
      ],
      "examples": [
        {
          "match": "SAS",
          "context": "g of the other endpoint data, SAS software version 9.4 or highe"
        },
        {
          "match": "SAS",
          "context": "ftware version 9.4 or higher (SAS Institute Inc.) or R version"
        },
        {
          "match": "R version 3.6.1",
          "context": "igher (SAS Institute Inc.) or R version 3.6.1 or higher (R Foundation for S"
        }
      ]
    },
    "error_measures": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "standard deviation"
      ],
      "examples": [
        {
          "match": "standard deviation",
          "context": "an, minimum, median, maximum, standard deviation (Std), and the 25th and 75th"
        }
      ]
    },
    "multiplicity_correction": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "secondary endpoint"
      ],
      "examples": [
        {
          "match": "Secondary endpoint",
          "context": "lment was set at 30 patients. Secondary endpoints including overall response,"
        },
        {
          "match": "secondary endpoint",
          "context": "not yet mature. Regarding the secondary endpoints, the R0 resection rate, safe"
        }
      ]
    },
    "confidence_intervals": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "95% ci"
      ],
      "examples": [
        {
          "match": "95% CI",
          "context": "OOTER: n, number of patients; 95% CIs are shown in parentheses. CA"
        },
        {
          "match": "95% CI",
          "context": "of patients; percentages and 95% CIs are shown in parentheses. CA"
        }
      ]
    },
    "comparative_stats": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "os"
      ],
      "examples": [
        {
          "match": "OS",
          "context": "erall response, R0 resection, OS, Becker regression grading (T"
        }
      ]
    },
    "regression_and_models": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "continuous"
      ],
      "examples": [
        {
          "match": "continuous",
          "context": "itored in near real time by a continuous toxicity monitoring board for"
        }
      ]
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "missing data",
        "dropout"
      ],
      "examples": [
        {
          "match": "missing data",
          "context": "as censored measurements, and missing data for the primary endpoint were"
        },
        {
          "match": "Missing data",
          "context": "ed at the time of submission. Missing data are indicated. Further inform"
        },
        {
          "match": "dropout",
          "context": "atients; accounting for a 10% dropout rate, the planned enrollment"
        }
      ]
    },
    "effect_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "excluded"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "spected, bone metastases were excluded with bone scintigraphy. Lapar"
        },
        {
          "match": "excluded",
          "context": "reastfeeding individuals were excluded. Adequate organ function was"
        },
        {
          "match": "excluded",
          "context": "oagulation. Participants were excluded from the study if any of the"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "sensitivity"
      ],
      "examples": [
        {
          "match": "sensitivity",
          "context": "r fusion proteins; known hypersensitivity to Chinese hamster ovary cell"
        },
        {
          "match": "sensitivity",
          "context": "any contraindication or hypersensitivity to components of the chemothe"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "staining"
      ],
      "examples": [
        {
          "match": "staining",
          "context": "entana Benchmark XT automated staining system (Ventana Medical Syste"
        },
        {
          "match": "staining",
          "context": "MSH6 all demonstrated nuclear staining in tumor cells. CPS was calcu"
        }
      ]
    }
  }
}